Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 142300.0
(1.14%)
KRW 142300.0
(1.14%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.38 Billion KRW | -277.86% |
| 2022 | 5.83 Billion KRW | 135.26% |
| 2021 | -16.55 Billion KRW | -1614.36% |
| 2020 | -965.67 Million KRW | -109.24% |
| 2019 | 10.45 Billion KRW | 19.39% |
| 2018 | 8.75 Billion KRW | -30.05% |
| 2017 | 12.51 Billion KRW | 43.65% |
| 2016 | 8.71 Billion KRW | -25.08% |
| 2015 | 11.62 Billion KRW | -1.85% |
| 2014 | 11.84 Billion KRW | 35.81% |
| 2013 | 8.72 Billion KRW | 550.82% |
| 2012 | 1.34 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 174.06 Million KRW | -84.73% |
| 2024 Q1 | 1.13 Billion KRW | -76.78% |
| 2023 Q3 | -11.81 Billion KRW | -208.15% |
| 2023 Q4 | 4.9 Billion KRW | 141.54% |
| 2023 FY | -10.38 Billion KRW | -277.86% |
| 2023 Q1 | 356.35 Million KRW | 41.1% |
| 2023 Q2 | -3.83 Billion KRW | -1175.77% |
| 2022 FY | 5.83 Billion KRW | 135.26% |
| 2022 Q1 | 1.83 Billion KRW | 131.79% |
| 2022 Q2 | 1.1 Billion KRW | -39.73% |
| 2022 Q3 | 2.65 Billion KRW | 139.3% |
| 2022 Q4 | 252.54 Million KRW | -90.48% |
| 2021 Q3 | -4.07 Billion KRW | -65.63% |
| 2021 Q1 | -4.24 Billion KRW | -183.21% |
| 2021 Q2 | -2.45 Billion KRW | 42.08% |
| 2021 Q4 | -5.78 Billion KRW | -42.08% |
| 2021 FY | -16.55 Billion KRW | -1614.36% |
| 2020 Q2 | 1.95 Billion KRW | 57.91% |
| 2020 FY | -965.67 Million KRW | -109.24% |
| 2020 Q4 | 5.09 Billion KRW | 155.12% |
| 2020 Q3 | -9.25 Billion KRW | -574.25% |
| 2020 Q1 | 1.23 Billion KRW | 147.13% |
| 2019 Q2 | 2.66 Billion KRW | -14.16% |
| 2019 Q1 | 3.1 Billion KRW | 297.51% |
| 2019 FY | 10.45 Billion KRW | 19.39% |
| 2019 Q4 | -2.62 Billion KRW | -135.85% |
| 2019 Q3 | 7.31 Billion KRW | 174.72% |
| 2018 Q2 | 3.66 Billion KRW | 47.4% |
| 2018 Q3 | 4.17 Billion KRW | 13.84% |
| 2018 Q4 | -1.56 Billion KRW | -137.62% |
| 2018 FY | 8.75 Billion KRW | -30.05% |
| 2018 Q1 | 2.48 Billion KRW | -9.5% |
| 2017 Q1 | 3.6 Billion KRW | 305.5% |
| 2017 FY | 12.51 Billion KRW | 43.65% |
| 2017 Q4 | 2.74 Billion KRW | -32.87% |
| 2017 Q2 | 2.07 Billion KRW | -42.51% |
| 2017 Q3 | 4.09 Billion KRW | 97.58% |
| 2016 FY | 8.71 Billion KRW | -25.08% |
| 2016 Q3 | 3.49 Billion KRW | -6.3% |
| 2016 Q4 | -1.75 Billion KRW | -150.23% |
| 2016 Q2 | 3.72 Billion KRW | 14.69% |
| 2016 Q1 | 3.24 Billion KRW | 12.42% |
| 2015 FY | 11.62 Billion KRW | -1.85% |
| 2015 Q3 | 3.36 Billion KRW | 25.62% |
| 2015 Q4 | 2.88 Billion KRW | -14.1% |
| 2015 Q2 | 2.67 Billion KRW | -0.71% |
| 2015 Q1 | 2.69 Billion KRW | 21.61% |
| 2014 Q2 | 3.04 Billion KRW | -19.5% |
| 2014 Q1 | 3.78 Billion KRW | 1442.33% |
| 2014 FY | 11.84 Billion KRW | 35.81% |
| 2014 Q4 | 2.21 Billion KRW | -20.72% |
| 2014 Q3 | 2.79 Billion KRW | -8.21% |
| 2013 Q2 | 2.88 Billion KRW | 24.01% |
| 2013 Q3 | 3.26 Billion KRW | 12.96% |
| 2013 Q1 | 2.32 Billion KRW | 0.0% |
| 2013 Q4 | 245.43 Million KRW | -92.48% |
| 2013 FY | 8.72 Billion KRW | 550.82% |
| 2012 FY | 1.34 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | -14.49 Billion KRW | 28.392% |
| ST Pharm Co.,Ltd. | 19.58 Billion KRW | 153.024% |
| ABL Bio Inc. | -2.64 Billion KRW | -292.295% |
| Cellid, Co., Ltd. | -11.61 Billion KRW | 10.582% |